Efficacy Evaluation of Hcy,HSP70 and H-FABP in Patients with Cerebral Infarction
Objective To evaluate the effects of homocysteine(Hcy),heat shock protein 70(HSP70)and cardiac fatty acid binding protein(H-FABP)on the treatment of cerebral infarction with butylphthalein combined with Tongqiao Huoxue Decoction.Methods A total of 82 patients with cerebral infarction admitted to People's Hospital of Luyi County from October 2021 to October 2022 were selected as the research objects,and treated with butylphthalein combined with Tongqiaohuoxuene decoction.The clinical data and serological indexes of the effective group and the ineffective group were compared,the factors influencing the therapeutic effect were analyzed by Logistic regression,and the value of serum Hcy,HSP70 and H-FABP alone and combined in predicting the therapeutic effect was analyzed,and the ROC curve was prepared.Results After 14 days of treatment,38 cases were obviously effective,30 cases were effective,14 cases were ineffective,and the total effective rate was 82.93%.There were 68 cases in the effective group and 14 cases in the ineffective group.The levels of Hcy,HSP70 and H-FABP in effective group were lower than those in ineffective group.The Hcy,HSP70 and H-FABP were all risk factors affecting the therapeutic effect of cerebral infarction patients.The AUC value of serum Hcy,HSP70 and H-FABP combined test was higher than that of single test,and the difference was statistically significant(ZHcy=3.038,ZHSP70=2.411,ZH-FABP=2.352,P＜0.05).Conclusion The combined detection of serum Hcy,HSP70 and H-FABP has a certain predictive value for the clinical efficacy of butylphthalein combined with Tongqiao Huoxue Decoction in the treatment of cerebral infarction patients.
cerebral infarctionbutylphthaleinTongqiao activating blood decoctionhomocysteineheat shock protein 70heart fatty acid binding protein
国家科技期刊平台
NSTL
万方数据
维普
